People channel feed

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

7 years ago
R&D
Pharma

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

7 years ago
R&D

One of the world's top ex­perts in coro­nary heart dis­ease is spear­head­ing a new gene edit­ing up­start out to trans­form the field

7 years ago
Startups
Cell/Gene Tx

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

7 years ago

Bill Haney's Sky­hawk spears an­oth­er mar­quee al­liance for its work drug­ging RNA in Take­da neu­ro pact

7 years ago
R&D
Pharma

Hit by set­backs, Lund­beck­'s Deb­o­rah Dun­sire inks a $400M cannabi­noid buy­out, adding a dis­cov­ery site

7 years ago
Deals
R&D

Pi­o­neer­ing mR­NA CEO Stéphane Ban­cel bags an eye-pop­ping $58M com­pen­sa­tion deal in wake of record IPO

7 years ago

As back­lash mounts in the wake of a dis­as­trous PhI­II flop, Ei­sai goes deep­er with 2 new hires

7 years ago
R&D
Pharma

Did a dis­as­ter crush your stock in 2018? These biotechs were hap­py to come up with some rich com­pen­sa­tion deals for the CEO any­way

7 years ago
Pharma

In­sys founder, for­mer ex­ecs face decades in jail af­ter be­ing found guilty in land­mark opi­oid case

7 years ago
Pharma

Dan O’Day’s to-do list for Gilead: Re­cruit a Kite CEO, press the ped­al on next-gen cell ther­a­pies and start buy­ing stuff

7 years ago
R&D

Ter­ry Rosen is look­ing to leave the thun­der­ing herd and blaze a new trail in PD-1 R&D

7 years ago
R&D

Mi­cro­bio­me play­er uBio­me puts founders on leave, in­ter­im CEO promis­es to as­sist in fed­er­al probe

7 years ago

Al­ler­gan CEO Saun­ders hangs on to chair­man's ti­tle, win­ning share­hold­er sup­port — but not by a big enough mar­gin to squelch crit­ics

7 years ago

173 to 1: Bris­tol-My­ers chief Caforio picked up a $19.4M com­pen­sa­tion deal af­ter lead­ing the charge for $74B Cel­gene buy­out

7 years ago

Gilead los­es yet an­oth­er ex­ec­u­tive as CFO Wash­ing­ton joins ex­o­dus, jump­ing to Al­pha­bet board

7 years ago

Share price blitzed, an­a­lysts in an up­roar af­ter lead PhI­II drug im­plodes — and Bio­gen un­veils a $2.5M raise for the CEO

7 years ago

An­a­lyst pens a barbed note to Bio­gen: Shed cau­tion, dump Alzheimer’s and re­tool at the top — go bold

7 years ago

Roiled by C-suite tur­moil and a CRL, Im­munomedics salutes CMO Rob Ian­none as he makes a quick ex­it

7 years ago

Af­ter promis­ing M&A and buy­backs to re­vive long-term prospects, Bio­gen re­fresh­es board with three ap­point­ments to en­thuse in­vestors

7 years ago

Fired for code of con­duct vi­o­la­tions, Ian Smith still grabbed a mul­ti­mil­lion-dol­lar stock pack­age at Ver­tex — but the cash bonus was axed

7 years ago

Len Schleifer and George Yan­copou­los once again land in the top ranks of the high­est paid ex­ecs in bio­phar­ma

7 years ago

‘Some­thing needs to change’: An Al­ler­gan an­a­lyst spells out why next week’s vote could still spark a ma­jor re­vamp

7 years ago
Pharma

Mar­tin Shkre­li gets a trans­fer to Brook­lyn fed­er­al prison in wake of his lat­est rule-break­ing es­capades be­hind bars

7 years ago
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times